The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor (3-Hole)
Comparison of Safety and Efficacy Among "3-Hole" Subxiphorid Approach, Trans Sternal Approach and VATS in Surgical Treatment of Anterior Mediastinal Tumor
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Yong-an Zhou, MD
- Phone Number: +86 029 84717544
- Email: zhou.yongan@163.com
Study Contact Backup
- Name: Qiang Lu, MD
- Phone Number: +86 029 84717548
- Email: luqianglu@126.com
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710038
- Recruiting
- Tangdu Hospital
-
Contact:
- Qiang Lu, MD
- Phone Number: +86 029 84717548
- Email: luqianglu@126.com
-
Contact:
- Yongan Zhou, MD
- Phone Number: +86 029 84717544
- Email: zhou.yongan@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- MG with thymic hyperplasia, thymoma or other anterior mediastinum disease
- Masaoka stagingⅠ-Ⅱ
- Thymoma without MG
- Mass diameter <10cm
- Inform Consent Form is signed
Exclusion Criteria:
- Unable to tolerate surgery
- myasthenic crisis
- Masaoka staging Ⅲ-Ⅳ
- Patients who have undergone previous surgery or radiotherapy
- pregnancy , breastfeeding or younger than 18 years old
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: "3-Hole" subxiphorid and subcostal approach
The patient were in the supine position with legs apart at about 45°, made a 2.0 cm incision below xiphoid process as the observation hole.
Then made two 0.5cm operation holes along bilateral rib arch at midclavicular line, two trocars were inserted into the two holes under the guidance of B-ultrasound.After that, carbon dioxide was pumped into the anterior mediastinum, the pressure was maintained at 8 mmH2O, ultrasound scalpel and a grasping forceps were inserted through the operating ports respectively.
Retrosternal space including bilateral lower poles of thymus, internal mammary arteries and phrenic nerves were exposed by both blunt and sharp dissection.
Then ultrasound scalpel were used to separate the thymus and its surrounding fat tissue, cut off thymic veins by ultrasound scalpel.For patients with myasthenia gravis, bilateral mediastinal pleurae and the affected adipose tissues had been thoroughly removed.
|
"3-Hole" subxiphorid and subcostal approach anterior mediastinum tumor resection
Other Names:
|
|
Experimental: Trans sternal approach
|
Trans sternal approach anterior mediastinum tumor resection
Other Names:
|
|
Experimental: VATS approach
|
Video-assisted thoracoscope anterior mediastinum tumor resection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amount of bleeding
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
|
Measured by the difference between the wet weight and dry weight of surgical gauze
|
Participants will be followed for the duration of hospital stay, an expected average of 5 days
|
|
Rate of conversions to thoracotomy
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
|
Only in "3-Hole" subxiphorid group and VATS group
|
Participants will be followed for the duration of hospital stay, an expected average of 5 days
|
|
Duration of operation
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
|
Participants will be followed for the duration of hospital stay, an expected average of 5 days
|
|
|
Mortality rate
Time Frame: up to 10 years
|
Death caused by operation or complications
|
up to 10 years
|
|
Overall survival
Time Frame: up to 10 years
|
From randomization to any cause of death
|
up to 10 years
|
|
Quality of life
Time Frame: up to 10 years after operation
|
Measured by EORTC QLQ-C30 (version 3) scale
|
up to 10 years after operation
|
|
Number of Participants with Adverse Events
Time Frame: up to 8weekss afte operation
|
up to 8weekss afte operation
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Thoracic Neoplasms
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Mediastinal Diseases
- Thoracic Diseases
- Myasthenia Gravis
- Mediastinal Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- TangduH717544
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.